Ms. Bauerlein brings success in scaling to
$300M+ revenue in direct-to-consumer business model and public
company execution as Gelesis plans to scale Plenity® to meet
growing consumer demand with its upcoming NYSE listing
Bauerlein joins Gelesis’ board of industry
veterans and luminaries who have deep expertise in
direct-to-consumer brands, healthcare, and biotechnology
Registration Statement filed in connection with
proposed business combination between Gelesis and Capstar declared
effective by SEC
Gelesis, a biotherapeutics company focused on excess weight and
metabolic disorders and the maker of Plenity®, announced the
appointment of senior financial executive Ali Bauerlein to its
Board of Directors. Ms. Bauerlein brings extensive experience in
SEC reporting, Sarbanes-Oxley compliance, investor communications,
strategic planning, business development, and corporate governance
in high-growth direct-to-consumer, insurance rentals, and
business-to-business revenue-generating companies. She co-founded
Inogen (NASDAQ: INGN), a global medical technology company offering
innovative respiratory products for use in the homecare setting,
and led it from start-up through initial public offering and
commercialization with $300M+ in annual revenue.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220105005205/en/
Gelesis, a biotherapeutics company
focused on excess weight and metabolic disorders and the maker of
Plenity®, announced the appointment of senior financial executive
Ali Bauerlein to its Board of Directors. (Photo: Business Wire)
The appointment comes as Gelesis ramps up its broad launch of
its commercial product, Plenity®. Gelesis aims to transform weight
management with Plenity, a clinically proven medical device made
from naturally derived building blocks. Plenity is available
currently by prescription via a telehealth consultation, with free,
unlimited follow-up visits as needed, and through traditional
healthcare prescribers.
Gelesis’ board includes healthcare and biotechnology luminaries
and veterans as well as experts in consumer brand building. Ms.
Bauerlein joins recent board appointee and marketing executive Jane
Wildman, a 25-year veteran of Procter & Gamble. Other board
members include Raju Kucherlapati, Ph.D., the Paul C. Cabot
Professor of Genetics and a Professor of Medicine at Harvard
Medical School and award-winning scientist and biotech
entrepreneur, and Paul Fonteyne, former President and CEO &
Chairman of Boehringer-Ingelheim USA who has experience on a number
of public and private boards of directors, along with Gelesis
founder and CEO Yishai Zohar and Dominic Perks, who founded and
runs an international investment firm. Upon completion of the
merger with Capstar, Clayton Christopher and Kathryn Cavanaugh, who
are founders and early investors in leading direct-to-consumer
brands, are expected to join the board of the post-merger public
company.
“It is an exciting time at Gelesis as we look toward becoming a
public company later this month and as we expand our commercial
business. Ali’s deep experience building a public healthcare
business that generates hundreds of millions in revenues with a
direct-to-consumer business model makes her the perfect addition to
our board and I’m delighted that she will be joining our audit
committee,” said Mr. Zohar.
“I am thrilled to be working with the Gelesis team and Board of
Directors,” said Ms. Bauerlein. “I believe their product can truly
make a difference for the vast number of people who struggle with
their weight. I am excited to be part of the commercialization of
this product and Gelesis’ transition to a public company.”
Gelesis and Capstar Special Purpose Acquisition Corp. (NYSE:
CPSR) announced in July that they entered into a definitive
business combination agreement, and the registration statement has
now been declared effective by the SEC. Upon completion of the
transaction, the combined company’s securities are expected to be
traded on the New York Stock Exchange under the symbol “GLS” later
this month.
About Gelesis
Gelesis is a consumer-centered biotherapeutics company advancing
a novel category of treatments for weight management and gut
related chronic diseases. Our non-systemic superabsorbent hydrogels
are the first and only made entirely from naturally derived
building blocks, and they are inspired by the composition (i.e.,
water & cellulose) and mechanical properties (e.g., elasticity
or firmness) of raw vegetables. They are conveniently administered
in capsules to create a much larger volume of small,
non-aggregating hydrogel pieces that become an integrated part of
the meals, and act locally in the digestive system. Our portfolio
includes Plenity®, an FDA-cleared product to aid in weight
management, as well as potential therapies in development for
patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
(NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional
Constipation. For more information, visit gelesis.com, or connect
with us on Twitter @GelesisInc.
Additional Information and Where to Find It
In July 2021, Gelesis entered into a business combination
agreement with Capstar Special Purpose Acquisition Corp. (NYSE:
CPSR) (“Capstar”), a special purpose acquisition company, as
amended in November 2021 and December 2021.
In connection with the business combination, Capstar has filed a
Registration Statement on Form S-4 with the SEC, which includes a
preliminary proxy statement/prospectus, which the SEC has declared
effective. On December 27, 2021, Capstar filed a definitive proxy
statement/prospectus relating to the proposed business combination
and mailed that definitive proxy statement/prospectus to its
shareholders. This press release is not a substitute for the
Registration Statement, the definitive proxy statement/final
prospectus or any other document that Capstar has or will send to
its stockholders in connection with the business combination. This
press release does not contain all the information that should be
considered concerning the proposed business combination and is not
intended to form the basis of any investment decision or any other
decision in respect of the proposed business combination.
Investors and security holders of Capstar are advised to read,
when available, the proxy statement/prospectus in connection with
Capstar’s solicitation of proxies for its special meeting of
stockholders to be held to approve the business combination (and
related matters) because the proxy statement/prospectus contains
important information about the business combination and the
parties to the business combination.
The definitive proxy statement/prospectus and other relevant
materials for the proposed business combination are being mailed to
shareholders of Capstar as of a record date that has been
established for voting on the proposed business combination.
Investors and security holders will also be able to obtain free
copies of the Registration Statement, the proxy
statement/prospectus and all other relevant documents filed or that
will be filed with the SEC by Capstar, without charge, once
available, through the website maintained by the SEC at
www.sec.gov. The documents filed by Capstar with the SEC also may
be obtained free of charge at Capstar’s website at
www.capstarspac.com, or by written request to: Capstar Special
Purpose Acquisition Corp., 405 West 14th Street, Austin, TX 78701,
Attention: R. Steven Hicks, Chief Executive Officer, (512)
340-7800.
Participants in the Solicitation
Capstar and its directors and executive officers may be deemed
participants in the solicitation of proxies from Capstar’s
shareholders with respect to the proposed business combination. The
names of those directors and executive officers and a description
of their interests in Capstar is contained in Capstar’s final
prospectus dated July 6, 2020 relating to its initial public
offering and in subsequent filings with the SEC, which are
available free of charge at the SEC’s web site at www.sec.gov. To
the extent such holdings of Capstar’s securities may have changed
since that time, such changes have been or will be reflected on
Statements of Changes in Beneficial Ownership on Form 4 filed with
the SEC. Additional information regarding the interests of such
participants will be contained in the proxy statement/prospectus
for the proposed business combination when available.
Gelesis and its directors and executive officers may also be
deemed to be participants in the solicitation of proxies from the
shareholders of Capstar in connection with the proposed business
combination. A list of the names of such directors and executive
officers and information regarding their interests in the proposed
business combination will be included in the proxy
statement/prospectus for the proposed business combination when
available.
Forward-Looking Statements
Certain statements, estimates, targets and projections in this
press release may constitute “forward-looking statements” within
the meaning of the federal securities laws. The words “anticipate,”
“believe,” continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “might,” “plan,” “possible,” “potential,” “predict,”
“project,” “should,” “strive,” “would” and similar expressions may
identify forward-looking statements, but the absence of these words
does not mean that statement is not forward looking.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Forward-looking statements include, but are not
limited to, the competitive environment in which Gelesis operates,
the expected future operating and financial performance and market
opportunities of Gelesis and statements regarding Gelesis’
expectations, hopes, beliefs, intentions or strategies regarding
the future. In addition, any statements that refer to projections,
forecasts, or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Gelesis and
Capstar assume no obligation and do not intend to update or revise
these forward-looking statements, whether as a result of new
information, future events, or otherwise. Gelesis and Capstar give
no assurance that any expectations set forth in this press release
will be achieved. Various factors could cause actual future
results, performance or events to differ materially from those
described herein. Some of the factors that may impact future
results and performance may include, without limitation: (i) the
size, demand and growth potential of the markets for Plenity®,
Gelesis’ other product candidates and its ability to serve those
markets; (ii) the degree of market acceptance and adoption of
Gelesis’ products; (iii) Gelesis’ ability to develop innovative
products and compete with other companies engaged in the weight
loss industry; (iv) Gelesis’ ability to complete successfully the
full commercial launch of Plenity® and its growth plans, including
new possible indications and the clinical data from ongoing and
future studies about liver and other diseases; (v) the inability of
the parties to successfully or timely consummate the proposed
business combination, including the risk that any required
regulatory approvals are not obtained, are delayed or are subject
to unanticipated conditions that could adversely affect the
combined company or the expected benefits of the business
combination or that the approval of the shareholders of Capstar is
not obtained; (vi) failure to realize the anticipated benefits of
the business combination, including as a result of a delay or
difficulty in integrating the businesses of Capstar and Gelesis;
(vii) the amount of redemption requests made by Capstar
shareholders; (viii) the ability of Capstar or the combined company
to issue equity or equity-linked securities or obtain debt
financing in connection with the proposed business combination or
in the future; (ix) the outcome of any legal proceedings that may
be instituted against Capstar, Gelesis, the combined company or
others following the announcement of the proposed business
combination and any definitive agreements with respect thereto; (x)
the ability to meet stock exchange listing standards at or
following the consummation of the proposed business combination;
(xi) the risk that the proposed business combination disrupts
current plans and operations of Gelesis as a result of the
announcement and consummation of the proposed business combination,
and as a result of the post-transaction company being a publicly
listed issuer; (xii) the regulatory pathway for Gelesis’ products
and responses from regulators, including the FDA and similar
regulators outside of the United States, (xiii) the ability of the
combined company to grow and manage growth profitably, maintain
relationships with customers and suppliers and retain Gelesis’
management and key employees; (xiv) costs related to the proposed
business combination, including costs associated with the
post-transaction company being a publicly listed issuer; (xiv)
changes in applicable laws or regulations; (xv) the possibility
that Gelesis or the combined company may be adversely affected by
other economic, business, regulatory and/or competitive factors;
(xvi) Gelesis’ estimates of expenses and profitability; (xvii)
ongoing regulatory requirements, (xviii) any competing products or
technologies that may emerge, (xix) the volatility of the
telehealth market in general, or insufficient patient demand; (xx)
the ability of Gelesis to defend its intellectual property and
satisfy regulatory requirements; (xxi) the impact of the COVID 19
pandemic on Gelesis’ business; (xxii) the limited operating history
of Gelesis; and (xxiii) those factors discussed in Capstar’s final
prospectus dated July 6, 2020, Annual Report on Form 10-K for the
fiscal year ended December 31, 2020 and the Registration Statement
on Form S-4, in each case, under the heading “Risk Factors”, and
other documents of Capstar filed, or to be filed, with the SEC, by
Capstar. These filings address other important risks and
uncertainties that could cause actual results and events to differ
materially from those contained in the forward-looking
statements.
Non-Solicitation
This press release is not a proxy statement or solicitation of a
proxy, consent or authorization with respect to any securities or
in respect of the proposed business combination and shall not
constitute an offer to sell or a solicitation of an offer to buy
the securities of Capstar, Gelesis or the combined company, nor
shall there be any sale of any such securities in any state or
jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction. No offer of
securities shall be made except by means of a prospectus meeting
the requirements of the Securities Act of 1933, as amended.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220105005205/en/
Media Relations Katie
Sullivan ksullivan@gelesis.com
Investor Relations Lynne
Collier, ICR lynne.collier@icrinc.com
Capstar Special Purpose ... (NYSE:CPSR)
過去 株価チャート
から 12 2024 まで 1 2025
Capstar Special Purpose ... (NYSE:CPSR)
過去 株価チャート
から 1 2024 まで 1 2025
